The 26th Congress of the European Hematology Association (EHA) 2021, 9-17 June, will see leading experts from around the globe gather virtually for a fantastic demonstration of the most ground-breaking research in the field of hematology.

Exciting data on promising biomarkers, CAR T-cell and NK-cell therapy, transplant research, novel drugs and more will be showcased across the spectrum of hematological diseases, including CLL, AML, multiple myeloma, lymphomas, CML, ALL, sickle cell disease, thalessemia, and beyond.

View all videos

EHA 2021

The 26th Congress of the European Hematology Association (EHA) 2021
09–17 June 2021 | Virtual Meeting

Marco Herling of @UniLeipzig discusses the safety and efficacy of tagraxofusp for the treatment of BPDCN:

🎥: http://ow.ly/hq9y50JGpAF

@EHA_Hematology #EHA2022 #RareDiseases #BPDCN

📣 Our latest podcast is now live! Join UK experts Graham Jackson & Martin Kaiser as they discuss myeloma treatment in the UK, highlighting updates from Muk Nine b: OPTIMUM, the importance of chromosome 1q & more!

🎧: http://ow.ly/Rmji50JGF6U

#MMsm #HemOnc #Myeloma

Want to learn more about myeloma treatment in the UK?

Join experts Graham Jackson (@profghjackson) & Martin Kaiser in this exclusive session as they discuss:

- Muk Nine b: OPTIMUM
- Myeloma XI
- Genomics in myeloma

& more!

👉http://ow.ly/qqgH50JEOpX👈

#MMsm #HemOnc

📣 Our latest podcast is now live! Join UK experts Graham Jackson & Martin Kaiser as they discuss myeloma treatment in the UK, highlighting updates from Muk Nine b: OPTIMUM, the importance of chromosome 1q & more!

🎧: http://ow.ly/Rmji50JGF6U

#MMsm #HemOnc #Myeloma

On June 24, the @US_FDA approved lisocabtagene maraleucel (liso-cel) for second-line treatment of adult patients with LBCL. The efficacy of liso-cel has been evaluated in the TRANSFORM study.

Find out more here:

👉http://ow.ly/QqNu50JJj3z👈

#LymSM #HemOnc #CARTcell #ImmunoOnc

Load More...

EHA 2021

The 26th Congress of the European Hematology Association (EHA) 2021
09–17 June 2021 | Virtual Meeting

The 26th Congress of the European Hematology Association (EHA) 2021, 9-17 June, will see leading experts from around the globe gather virtually for a fantastic demonstration of the most ground-breaking research in the field of hematology.

Exciting data on promising biomarkers, CAR T-cell and NK-cell therapy, transplant research, novel drugs and more will be showcased across the spectrum of hematological diseases, including CLL, AML, multiple myeloma, lymphomas, CML, ALL, sickle cell disease, thalessemia, and beyond.

View all videos

Marco Herling of @UniLeipzig discusses the safety and efficacy of tagraxofusp for the treatment of BPDCN:

🎥: http://ow.ly/hq9y50JGpAF

@EHA_Hematology #EHA2022 #RareDiseases #BPDCN

📣 Our latest podcast is now live! Join UK experts Graham Jackson & Martin Kaiser as they discuss myeloma treatment in the UK, highlighting updates from Muk Nine b: OPTIMUM, the importance of chromosome 1q & more!

🎧: http://ow.ly/Rmji50JGF6U

#MMsm #HemOnc #Myeloma

Want to learn more about myeloma treatment in the UK?

Join experts Graham Jackson (@profghjackson) & Martin Kaiser in this exclusive session as they discuss:

- Muk Nine b: OPTIMUM
- Myeloma XI
- Genomics in myeloma

& more!

👉http://ow.ly/qqgH50JEOpX👈

#MMsm #HemOnc

📣 Our latest podcast is now live! Join UK experts Graham Jackson & Martin Kaiser as they discuss myeloma treatment in the UK, highlighting updates from Muk Nine b: OPTIMUM, the importance of chromosome 1q & more!

🎧: http://ow.ly/Rmji50JGF6U

#MMsm #HemOnc #Myeloma

On June 24, the @US_FDA approved lisocabtagene maraleucel (liso-cel) for second-line treatment of adult patients with LBCL. The efficacy of liso-cel has been evaluated in the TRANSFORM study.

Find out more here:

👉http://ow.ly/QqNu50JJj3z👈

#LymSM #HemOnc #CARTcell #ImmunoOnc

Load More...

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter